Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HDM1002 Tablets for weight management in overweight and obese adults
CTR20251246Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of conveglipron in obesity, Overweight, sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Apr 2025; status: active.
02
Drugs
conveglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20251246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251246.